SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Sino Biopharmaceutical Limited SBHMY OTC

Other OTC • Healthcare • Biotechnology • HK • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Sino Biopharmaceutical Limited (SBHMY) is a Biotechnology company in the Healthcare sector, currently trading at $15.89. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $31.0B, +2.8%/yr average growth. Net income is $2.3B, growing at -12.7%/yr. Net profit margin is 7.4% (thin). Gross margin is 82.1% (+2.2 pp trend).

Balance sheet: total debt is $16.1B against $30.7B equity (Debt-to-Equity (D/E) ratio 0.52, moderate). Current ratio is 1.37 (adequate). Debt-to-assets is 21.1%. Total assets: $76.1B.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 30/100 (Fail), Past 100/100 (Pass), Health 67/100 (Partial), Moat 84/100 (Pass), Future ?/100 (Fail), Income 45/100 (Partial).

SBHMY SharesGrow Score Overview

71/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 30/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 84/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 45/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SBHMY

SBHMY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

SBHMY: +2.8%/yr revenue is, -12.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

SBHMY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet SBHMY: Debt-to-Equity (D/E) ratio 0.52 (moderate), Current ratio is 1.37 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

SBHMY: Gross margin is 82.1% (+2.2 pp trend), $14B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 84/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

SBHMY: Net profit margin is 7.4%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range8.755-20.16

Volume100

Avg Volume (30D)7

Market Cap$14.2B

Beta (1Y)0.72

Dividend Yield$0.2305

Share Statistics

EPS (TTM)2.60

Shares Outstanding$900.12M

IPO Date2017-09-05

Employees24,379

CEOS. Y. Tse

Financial Highlights & Ratios

Revenue (TTM)$30.97B

Gross Profit$25.41B

EBITDA$7.78B

Net Income$2.28B

Operating Income$6.63B

Total Cash$22.56B

Total Debt$16.08B

Net Debt$8.69B

Total Assets$76.06B

Price / Earnings (P/E)6.1

Price / Sales (P/S)0.46

Analyst Forecast

Company Info

CountryHK

ExchangeOther OTC

CurrencyUSD

ISINUS82937X1037

Price Chart

SBHMY

Sino Biopharmaceutical Limited ↗ · Other OTC

Healthcare • Biotechnology

8.76 52WK RANGE 20.16

People Also View

Centessa Pharmaceuticals plc

Tarsus Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc.

Entrada Therapeutics, Inc.

XOMA Corporation

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message